Merck & Co. reported an 8.9% quarter-over-quarter revenue increase in Q3, reaching $18.09 billion and beating analyst estimates. Keytruda and Keytruda Qlex sales grew 5.6% year-over-year to $8.1 billion, while Winrevair sales rose 18% sequentially to $694 million. Despite strong sales, the stock shows signs of being overbought, prompting a downgrade to Hold with an expected price pullback to $127 per share.
Merck & Co. shares are trading at USD 147.55 on Pluang as of Oct 29, 2026 21:02 WIB, showing a strong 1-day gain of 4.56%. The stock's market capitalization stands at $347.70 billion, reflecting its significant size in the health sector. Trading volume reached 8,193,716 shares, with investor sentiment evenly split between buying and selling at 50% each.
Merck exceeded third-quarter earnings and revenue expectations, driven by strong sales of its immunotherapy drug Keytruda and its newer injectable form, Qlex, which posted $830 million in sales—the highest since its 2025 launch. The company raised it...
Moderna's stock climbed 4% after strong Phase 3 melanoma vaccine trial results, despite a downgrade from William Blair citing valuation concerns after a 636% yearly gain. The trial showed Moderna and Merck's vaccine reduced melanoma recurrence risk b...
Eli Lilly, Merck, and Gilead Sciences are set to report their Q3 2026 earnings on October 29, with Eli Lilly facing lowered EPS estimates amid strong GLP-1 drug demand, Merck dealing with tough comparisons for its cancer drug Keytruda, and Gilead man...
The global CRISPR market is forecasted to grow from $3.48 billion in 2026 to $6.12 billion by 2031, at a CAGR of 12%. Growth is fueled by expanding use in drug discovery, gene therapy, precision medicine, and agriculture, alongside technological adva...
Moderna's stock fell about 7.4% following the release of Phase 3 trial data for its experimental cancer vaccine, intismeran, developed with Merck. The results tempered investor enthusiasm, reflecting that expectations had been very high. Merck's shar...
